= Message - Pharmacy/Treatment Refill Authorization Request
:render_as: Message Page
:v291_section: 4A.3.16

The RDE/RRE is used to communicate a refill authorization request originating with the pharmacy. This message replicates the standard RDE message with a different trigger event code to indicate the specific use case of a refill authorization request.

RDE^O25^RDE_O11: Pharmacy/Treatment Refill Authorization Request

[width="100%",cols="34%,47%,9%,,10%",options="header",]

|===

|Segments |Description |Status |Chapter |

|MSH |Message Header | |2 |

|[\{ARV}] |Access Restrictions | |3 |

|[\{ SFT }] |Software | |2 |

|[ UAC ] |User Authentication Credential | |2 |

|[\{ NTE }] |Notes and Comments (for Header) | |2 |

|[ |--- PATIENT begin | | |

|PID |Patient Identification | |3 |

|[ PD1 ] |Additional Demographics | |3 |

|[\{ GSP }] |Person Gender and Sex | | |3

|[\{ GSR }] |Recorded Gender and Sex | | |3

|[\{ GSC }] |Sex Parameter for Clinical Use | | |3

|[\{PRT}] |Participation (for Additional Demographics) | |7 |

|[\{ NTE }] |Notes and Comments (for Patient ID) | |2 |

|[\{ ARV }] |For backwards compatibility only as of V2.9. |B |3 |

|[ |--- PATIENT_VISIT begin | | |

|PV1 |Patient Visit | |3 |

|[ PV2 ] |Patient Visit â€“ Additional Info | |3 |

|[\{PRT}] |Participation (for Patient Visit) | |7 |

|[\{ ARV }] |For backwards compatibility only as of V2.9. |B |3 |

|] |--- PATIENT_VISIT end | | |

|[\{ |--- INSURANCE begin | | |

|IN1 |Insurance | | |

|[ IN2 ] |Insurance Additional Information | |6 |

|[ IN3 ] |Insurance Additional Information, Certification | |6 |

|}] |--- INSURANCE end | | |

|[ GT1 ] |Guarantor | |6 |

|[\{ AL1 }] |Allergy Information | |3 |

|] |--- PATIENT end | | |

|\{ |--- ORDER begin | | |

|ORC |Common Order | |4 |

|[\{PRT}] |Participation (for Order) | |7 |

|[\{ |--- TIMING begin | | |

|TQ1 |Timing/Quantity | |4 |

|[\{ TQ2 }] |Timing/Quantity Order Sequence | |4 |

|}] |--- TIMING end | | |

|[ |--- ORDER_DETAIL begin | | |

|RXO |Pharmacy/Treatment Prescription Order | |4A |

|[\{PRT}] |Participation (for RXO) | |7 |

|[\{ NTE }] |Notes and Comments (for RXO) | |2 |

|\{ RXR } |Pharmacy/Treatment Route | |4A |

|[\{ |--- COMPONENTS begin | | |

|RXC |Pharmacy/Treatment Component (for RXO) | |4A |

|[\{ NTE }] |Notes and Comments (for each RXC) | |2 |

|}] |--- COMPONENTS end | | |

|] |--- ORDER_DETAIL end | | |

|RXE |Pharmacy/Treatment Encoded Order | |4A |

|[\{PRT}] |Participation (for RXE) | |7 |

|[\{ NTE }] |Notes and Comments (for RXE) | |2 |

|\{ |--- TIMING_ENCODED begin | | |

|TQ1 |Timing/Quantity | |4 |

|[\{ TQ2 }] |Timing/Quantity Order Sequence | |4 |

|} |--- TIMING_ENCODED end | | |

|[\{ |--- PHARMACY_TREATMENT_INFUSION_ORDER begin | | |

|RXV |Pharmacy/Treatment Infusion Order | |4A |

|[\{PRT}] |Participation (for RXV) | |7 |

|[\{ NTE }] |Notes and Comments (for RXV) | |2 |

|\{ |--- TIMING_ENCODED begin | | |

|TQ1 |Timing/Quantity | |4 |

|[\{ TQ2 }] |Timing/Quantity Order Sequence | |4 |

|} |--- TIMING_ENCODED end | | |

|}] |--- PHARMACY_TREATMENT_INFUSION_ORDER end | | |

|\{ RXR } |Pharmacy/Treatment Route | |4A |

|[\{ RXC }] |Pharmacy/Treatment Component (for RXE) | |4A |

|[\{ CDO }] |Cumulative Dosage Segment | |4A |

|[\{ |--- OBSERVATION begin | | |

|OBX |Results | |7 |

|[\{PRT}] |Participation (for OBX) | |7 |

|[\{ NTE }] |Notes and Comments (for OBX) | |2 |

|}] |--- OBSERVATION end | | |

|[\{ FT1 }] |Financial Detail | |6 |

|[ BLG ] |Billing Segment | |4 |

|[\{ CTI }] |Clinical Trial Identification | |7 |

|} |--- ORDER end | | |

|===

[width="100%",cols="18%,30%,6%,23%,23%",options="header",]

|===

|Acknowledgement Choreography | | | |

|RDE^O25^RDE_O11 | | | |

|Field name |Field Value: Original mode |Field value: Enhanced mode | |

|MSH-15 |Blank |NE |NE |AL, SU, ER

|MSH-16 |Blank |NE |AL, SU, ER |AL, SU, ER

|Immediate Ack |- |- |- |ACK^O25^ACK

|Application Ack |RRE^O26^RRE_O12 |- |RRE^O26^RRE_O12 |RRE^O26^RRE_O12

|===

[message-tabs, ["RDE^O25^RDE_O25", "RDE^O25 Interaction", "RRE^O26^RRE_O26", "RRE^O26 Interaction"]]

